Since Malvinder Mohan Singh announced last week that he would sell leading Indian generic drug maker Ranbaxy to Daiichi Sankyo of Japan, incredulous friends have deluged him with messages.

“They said: ‘Have you actually sold your shareholding?’ ” said Mr Singh, Ranbaxy’s chief executive, in an interview at his office on the outskirts of New Delhi.